Date Filed | Type | Description |
10/05/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
09/26/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/25/2023 |
4
| Cherington Charles (10% Owner) has filed a Form 4 on Eterna Therapeutics Inc.
Txns:
| Bought options to buy
@ $3300000, valued at
$0 Bought 2,307,692 warrants
@ $0.125, valued at
$288.5k
|
|
08/23/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
08/23/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
08/14/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/10/2023 |
4
| BINDER BRANT (Former director) has filed a Form 4 on Eterna Therapeutics Inc. |
08/10/2023 |
4
| WAGNER RICHARD W (Former director) has filed a Form 4 on Eterna Therapeutics Inc. |
08/10/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
08/02/2023 |
8-K
| Investor presentation |
07/26/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
07/26/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
07/26/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
07/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/18/2023 |
4
| WAGNER RICHARD W (Director) has filed a Form 4 on Eterna Therapeutics Inc.
Txns:
| Bought options to buy
@ $2.86, valued at
$0 Bought 83,916 warrants
@ $2.61, valued at
$219k
|
|
07/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
07/18/2023 |
4
| Freebird Partners LP (10% Owner) has filed a Form 4 on Eterna Therapeutics Inc.
Txns:
| Bought 262,237 options to buy
@ $2.86, valued at
$750k
Bought 524,474 warrants
@ $2.61, valued at
$1.4M
|
|
07/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
07/11/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
07/11/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
07/11/2023 |
8-K
| Quarterly results |
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/05/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
05/05/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
05/05/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
05/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/02/2023 |
8-K
| Quarterly results |
04/25/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
04/25/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
04/20/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
04/14/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
04/04/2023 |
SC 13G/A
| Freebird Partners LP reports a 12.6% stake in Eterna Therapeutics Inc. |
04/04/2023 |
3
| Freebird Partners LP (10% Owner) has filed a Form 3 on Eterna Therapeutics Inc. |
|